Key facts
- This page summarizes Robert Lisicki's Form 4 filing for Cadrenal Therapeutics, Inc. (CVKD).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 24 Jan 2025, 18:09.
Robert Lisicki - 23 Jan 2025 Form 4 Insider Report for Cadrenal Therapeutics, Inc. (CVKD)
- Reporting relationship
- Director
- Issuer ticker
- CVKD
- Reported as of
- 23 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 24 Jan 2025, 18:09:38 UTC
- Prior SEC filing
- 11 Dec 2024
- Next SEC filing
- 03 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Matthew K. Szot, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert Lisicki filed Form 4 for Cadrenal Therapeutics, Inc. (CVKD) on 24 Jan 2025.
Change
- Previous filing in this sequence was filed on 11 Dec 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CVKD
transaction
Derivative
Stock Options
Award
- Transaction value
- $0
- Shares
- +20,000
- Change %
- Price
- $0.000000
- Shares after
- 20,000
- Date
- 23 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,000
- Exercise price
- $19.79
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
These options vest pro rata on a monthly basis over 12 months commencing on February 1, 2025.